Welcome to our dedicated page for Nanobiotix S.A. news (Ticker: $NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix S.A. stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nanobiotix S.A.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nanobiotix S.A.'s position in the market.
Rhea-AI Summary
Nanobiotix (NBTX) announces the monthly publication of the total number of voting rights and shares comprising its capital, in accordance with the French Commercial Code and the General Regulation of the French Financial Markets Authority. As of December 31, 2023, Nanobiotix had 47,133,328 shares outstanding, with a total of 48,849,317 voting rights, of which 48,827,199 were exercisable.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
-
Rhea-AI Summary
Nanobiotix (NANO - NBTX) Announces Global Development and Commercialization Agreement for NBTXR3 with Janssen
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
-
Rhea-AI Summary
Nanobiotix (NANO:FP) announces the publication of the total number of voting rights and shares outstanding as of November 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.72%
Tags
Rhea-AI Summary
Nanobiotix (NANO – NBTX) has received approximately €55.5 million (equivalent to approximately $58.7 million) in gross proceeds from a subscription by Johnson & Johnson Innovation, extending its cash runway into mid-2025. This includes a closing of a subscription for 901,256 additional ordinary shares of the Company, in the form of restricted American Depositary Shares (ADSs), for an aggregate amount of $4.8 million. The subscription by JJDC was conditioned upon the approval of the French Ministry of Economy. The Company intends to use the net proceeds from the placement for its working capital requirements until mid-2025, assuming the receipt of the first milestone payment from Janssen Pharmaceutica NV under the Company’s License Agreement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
-
Rhea-AI Summary
Nanobiotix (NANO –– NBTX) reports a $2.5 billion global licensing, co-development, and commercialization agreement for NBTXR3. The company presented promising data for NBTXR3 in head and neck cancer and locally advanced pancreatic cancer. They raised €50.9 million, successfully removed the EIB cash covenant, and have multiple clinical readouts over the next 18 months. The company's financial runway is extended into 2Q 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
-
News
Rhea-AI Summary
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX) will report its financial results for the third quarter of 2023 on November 13, 2023. A conference call and webcast are scheduled for November 14, 2023, at 8:00 AM ET / 2:00 PM CET. The call will include a review of operational progress, business activities, and the latest data presented at the 2023 Annual Congress of the European Society for Medical Oncology (ESMO).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.72%
Tags
Rhea-AI Summary
Nanobiotix (NANO:FP) Announces Monthly Disclosure of Total Voting Rights and Shares Outstanding
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
-
Rhea-AI Summary
NANOBIOTIX (NANO: Euronext, NBTX: NASDAQ) closes global follow-on offering, raising approximately $53.8 million. The offering includes 3,786,907 ADS in the U.S. and 2,492,223 Ordinary Shares in Europe, with JJDC subscribing for $25.0 million of the Company's restricted ADSs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
-
Rhea-AI Summary
Nanobiotix, a biotechnology company focusing on cancer treatment, announces the availability of its listing prospectus approved by the French Financial Markets Authority. The company has raised approximately $50 million through two share capital increases, with qualified investors subscribing for $30 million and Johnson & Johnson Innovation subscribing for $20.2 million. The funds raised will bring Nanobiotix's gross proceeds to $55 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
Rhea-AI Summary
Nanobiotix, a late-clinical stage biotechnology company, has priced its global follow-on offering. The offering consists of 3,106,907 American Depositary Shares (ADSs) in the United States at $5.36 per ADS and 2,492,223 Ordinary Shares in Europe at €5.07 per share. The aggregate gross proceeds are expected to be approximately $55 million. Jefferies LLC, Leerink Partners, and Guggenheim are acting as global coordinators and joint bookrunners for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.01%
Tags
Nanobiotix S.A.
Nasdaq:NBTX
NBTX Rankings
NBTX Stock Data
344.38M
20.76M
19.68%
0.11%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
Paris
About NBTX
nanobiotix (euronext: nano / isin: fr0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the treatment of cancer. the company’s first-in-class, proprietary technology, nanoxray, enhances radiotherapy energy with a view to providing a new, more efficient treatment for cancer patients. nanoxray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration. nbtxr3 is being evaluated in: soft tissue sarcoma (sts), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). additionally, head and neck cancer and rectal cancer trials led by nanobiotix’s taiwanese partner, pharmaengine, are underway in the asia pacific region. the company started a new preclinical research program in immuno-oncology with its lea